From the FDA Drug Label
Pediatric Use Safety and effectiveness of propranolol in pediatric patients have not been established Bronchospasm and congestive heart failure have been reported coincident with the administration of propranolol therapy in pediatric patients.
The safety of Rupall for an 8-year-old child weighing 45kg has not been established. There is a risk of bronchospasm and congestive heart failure in pediatric patients. 1 1
From the Research
Rupall (rupatadine) is not recommended for an 8-year-old child weighing 45kg without a healthcare provider's assessment, as the most recent and highest quality study 2 indicates that rupatadine is safe and well tolerated in patients over 2 years old, but its use in children under 12 years old is not widely approved. The safety and dosing of rupatadine for children depend on local regulatory approvals and individual health factors.
- In many regions, rupatadine is approved for children 2-11 years old at a dose of 2.5-5mg once daily, with weight being a consideration for proper dosing.
- However, this medication may cause side effects like drowsiness, headache, or fatigue.
- The child's medical history, other medications, and specific allergic condition must be evaluated before use.
- Additionally, the 45kg weight puts this child at the higher end of the pediatric weight range, which might affect dosing decisions. Please consult with a pediatrician or allergist who can review the child's complete medical information and provide appropriate guidance for this specific situation, as they can assess the potential benefits and risks of rupatadine treatment, as noted in studies 3, 4, 5.